Dr. Van Tine on Identifying Biomarkers in Sarcomas

Brian A. Van Tine, MD, PhD
Published: Monday, Aug 12, 2013

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.

Every metabolite that can be identified is a biomarker, Van Tine says. In looking at the entire metabolic structure, researchers are able to look at every change in metabolism that occurs naturally or with a drug. This allows for the development of targeted therapies that are specific to a patient and metabolic pathway.

The connection between metabolism and targeted therapies allows for the treatment of sarcomas, which are very chemoselective, Van Tine says.

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.

Every metabolite that can be identified is a biomarker, Van Tine says. In looking at the entire metabolic structure, researchers are able to look at every change in metabolism that occurs naturally or with a drug. This allows for the development of targeted therapies that are specific to a patient and metabolic pathway.

The connection between metabolism and targeted therapies allows for the treatment of sarcomas, which are very chemoselective, Van Tine says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x